2020
Quality and Publication of Emergency Medicine Trials Registered in ClinicalTrials.gov
Calvocoressi L, Reynolds J, Johnson B, Warzoha MM, Carroll M, Vaca FE, Post L, Dziura J. Quality and Publication of Emergency Medicine Trials Registered in ClinicalTrials.gov. Western Journal Of Emergency Medicine 2020, 21: 295-303. PMID: 32191186, PMCID: PMC7081876, DOI: 10.5811/westjem.2019.12.44096.Peer-Reviewed Original ResearchConceptsClinical trialsEM trialsKaplan-Meier curvesLog-rank testNational clinical trialClinical trial researchChi-square testEM studiesTrial qualityInterventional trialsPeer-reviewed journalsMedicine trialsNeurological conditionsLarger sample sizeTrial researchStudy characteristicsStudy periodTrialsNational InstituteSubspecialty areasBlindingPeriodic assessmentDescriptive statisticsHigher proportionIndustry funding
2011
Nuclear expression of S100A4 calcium‐binding protein increases cholangiocarcinoma invasiveness and metastasization
Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, Nardo G, Sonzogni A, Colledan M, Furlanetto A, Bassi N, Massani M, Cillo U, Mescoli C, Indraccolo S, Rugge M, Okolicsanyi L, Strazzabosco M. Nuclear expression of S100A4 calcium‐binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011, 54: 890-899. PMID: 21618579, PMCID: PMC3753582, DOI: 10.1002/hep.24466.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsApoptosisBile Duct NeoplasmsBile Ducts, IntrahepaticCell MovementCell NucleusCell ProliferationCholangiocarcinomaFemaleHumansMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisPrognosisS100 Calcium-Binding Protein A4S100 ProteinsConceptsSurgical resectionCCA cellsNuclear expressionCCA patientsMetastatic propertiesSevere combined immunodeficiency miceTFK-1Time of surgeryRole of S100A4Log-rank testCombined immunodeficiency miceExpression of S100A4EGI-1 cellsHuman CCA cell linesPotential therapeutic targetMMP-9 secretionCCA cell linesHuman liver samplesCholangiocarcinoma invasivenessNuclear S100A4Severe prognosisPatient survivalPoor prognosisNeoplastic ductsImmunodeficiency mice